SLC5A2 and type 2 diabetes mellitus: Some meta-analyses were published before or during the preparation this manuscript, which generally showed that SGLT2 inhibitors can exert the benefit in reducing AKI in patients with T2D, heart failure, or CKD; and this benefit does not vary with various characteristics, such as the diagnosis of the patients and type of SGLT2 inhibitors (Menne et al., 2019; Neuen et al., 2019; Zhao et al., 2020; Qiu et al., 2021; Baigent et al., 2022; Gong et al., 2022; Rigato et al., 2023).